---
document_datetime: 2025-01-07 11:45:38
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aimovig-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: aimovig-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.9708665
conversion_datetime: 2025-12-27 16:17:33.259456
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Aimovig

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0034/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 19/12/2024                          |                                             | Annex II and PL                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor   |            |     |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10699 /202405 | Periodic Safety Update EU Single assessment - erenumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 28/11/2024 | n/a | PRAC Recommendation - maintenance |
| IA/0032/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 28/06/2024 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                        |            |            |                 |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| II/0030             | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                   | 18/04/2024 | n/a        |                 |                                   |
| IAIN/0031/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.7 - Administrative change - Deletion of | 13/03/2024 | n/a        |                 |                                   |
| PSUSA/10699 /202305 | Periodic Safety Update EU Single assessment - erenumab                                                                                                                                                                                                                                             | 30/11/2023 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0029/G         | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                | 10/08/2023 | 27/05/2024 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                 |            |            |                       |                                                                                                                                                                                                                                                                       |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0027     | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                 | 22/06/2023 | n/a        |                       |                                                                                                                                                                                                                                                                       |
| II/0026/G   | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 15/06/2023 | 27/05/2024 | SmPC                  | Update of section 5.1 of the SmPC in order to update clinical efficacy and safety information based on final results from studies CAMG334A2301 (LIBERTY) and CAMG334ADE01 (HER-MES). For more information, please refer to the Summary of Product Characteristics.    |
| IB/0025     | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                           | 21/04/2023 | n/a        |                       |                                                                                                                                                                                                                                                                       |
| R/0024      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                | 15/12/2022 | 20/02/2023 | SmPC, Annex II and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Aimovig in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10699 | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                          | 01/12/2022 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| /202205             | erenumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IB/0021/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 11/07/2022 | n/a        |             |                                   |
| IG/1521             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                         | 23/06/2022 | n/a        |             |                                   |
| IB/0020             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                  | 15/12/2021 | 13/06/2022 | SmPC and PL |                                   |
| PSUSA/10699 /202105 | Periodic Safety Update EU Single assessment - erenumab                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 02/12/2021 | n/a        |             | PRAC Recommendation - maintenance |
| N/0019              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                           | 28/10/2021 | 13/06/2022 | PL          |                                   |
| II/0017             | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                                                                                                                                                                                                        | 21/10/2021 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

| II/0016             | B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a biological/immunological medicinal product or a new bioequivalence study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/07/2021   | n/a        |             |                                                                                                                                                                                                                                                                                |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10699 /202011 | Periodic Safety Update EU Single assessment - erenumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 10/06/2021   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                              |
| II/0013/G           | This was an application for a group of variations. Update of section 4.8 of the SmPC in line with revised clinical safety data. Submission of the study report from 5-year open- label study 20120178 with consequential changes to the Section 4.8 and Section 5.1 of the SmPC as well as an update of the EU RMP Type IA variation to the include ATC code for erenumab. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data A.6 - Administrative change - Change in ATC Code/ATC Vet Code | 06/05/2021   | 13/06/2022 | SmPC and PL | The SmPC section 4.8 has been updated to include rash, oral sores and alopecia. The SmPC and the Risk Management Plan has also been updated to reflect the results of open-label study 20120178. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| PSUSA/10699 /202005   | Periodic Safety Update EU Single assessment - erenumab                                                                                                                                                                                                                                                                                                                            | 14/01/2021   | n/a        |                 | PRAC Recommendation - maintenance                                                                                                          |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0014/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 23/11/2020   | n/a        |                 |                                                                                                                                            |
| PSUSA/10699 /201911   | Periodic Safety Update EU Single assessment - erenumab                                                                                                                                                                                                                                                                                                                            | 25/06/2020   | 25/08/2020 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10699/201911. |
| IAIN/0011             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                            | 31/03/2020   | 25/08/2020 | Annex II and PL |                                                                                                                                            |
| IAIN/0010/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer                                                                                                                  | 31/03/2020   | 25/08/2020 | Annex II and PL |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0008/G           | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                 | 10/03/2020 | n/a        |             |                                                                                                                                            |
| PSUSA/10699 /201905 | Periodic Safety Update EU Single assessment - erenumab                                                                                                                                                                                                                                                                                                                                                                                                   | 12/12/2019 | 13/02/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10699/201905. |
| IB/0007             | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                                                                  | 29/10/2019 | n/a        |             |                                                                                                                                            |
| PSUSA/10699 /201811 | Periodic Safety Update EU Single assessment - erenumab                                                                                                                                                                                                                                                                                                                                                                                                   | 27/06/2019 | 23/08/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10699/201811. |
| II/0003/G           | This was an application for a group of variations. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 25/07/2019 | 13/02/2020 | Annex II    |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                        |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IAIN/0005/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 28/06/2019 | n/a        |                        |
| X/0001      | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 28/02/2019 | 26/04/2019 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| IAIN/0002/G   | This was an application for a group of variations.   | 14/01/2019   | n/a   |
|---------------|------------------------------------------------------|--------------|-------|